在HRAS突变的头部和部状细胞癌中,蒂法尼布的进化动态
Sankar Jagadeeshan1, Kushal Suryamohan2, Nara Shin2
1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
一名患有复发性转移性头支状细胞癌 (HNSCC) 的患者携带HRAS突变,获得了对tipifarnib的持久反应. 与PI3K抑制剂的联合治疗增强了抗瘤疗效,这表明HRAS驱动的HNSCC的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 头角状细胞癌 (HNSCC) 是一种流行癌症,在复发/转移 (R/M) 阶段的预后不佳.
- 目前的治疗方法对先进的HNSCC患者提供有限的益处.
更多相关视频
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
07:52In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
Published on: November 2, 2020
相关概念视频
Abnormal Proliferation
The Ras Gene
Ras is a...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
